BridgeMD
A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC
EU CTIS ID: 2025-523576-23-00
What this study is testing
The main goal of the study is to compare pumitamig and durvalumab to see which medicine does a better job at slowing down the worsening of the stage III NSCLC.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- participants with unresectable Stage III NSCLC whose cancer did not get worse after chemoradiation
- Participants can have any level of PD-L1 expression and must be in good overall health
You likely can't join if
- significant cardiovascular disease
- significant lung disease (within 6 months prior to randomization) or history of interstitial lung disease or pneumonitis requiring treatment with systemic steroids
- significant risk of pulmonary hemorrhage
- a history of abdominal fistula or gastrointestinal perforation within 6 months prior of randomization
- certain types of mutations (EGFR mutations or ALK rearrangements)
- evidence of major coagulation disorders
The study team makes the final eligibility decision.
Where it's taking place
- Argentina
- Singapore
- Canada
- Australia
- Mexico
- India
- Korea, Republic of
- United States
- United Kingdom
- Switzerland
- Hong Kong
- Thailand
- Chile
- Taiwan
- China
- Turkey
- Brazil
- Japan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Argentina; Singapore; Canada; Australia; Mexico; India and 12 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.